The Manufacturers Life Insurance Company increased its stake in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) by 7.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,304 shares of the biopharmaceutical company’s stock after purchasing an additional 1,275 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.06% of Revance Therapeutics worth $483,000 as of its most recent SEC filing.
Other institutional investors also recently made changes to their positions in the company. JPMorgan Chase & Co. grew its stake in shares of Revance Therapeutics by 4.8% during the second quarter. JPMorgan Chase & Co. now owns 3,626,603 shares of the biopharmaceutical company’s stock worth $95,743,000 after purchasing an additional 166,759 shares during the period. QS Investors LLC acquired a new stake in shares of Revance Therapeutics during the second quarter worth $1,564,000. Vanguard Group Inc. grew its stake in shares of Revance Therapeutics by 7.3% during the second quarter. Vanguard Group Inc. now owns 931,623 shares of the biopharmaceutical company’s stock worth $24,595,000 after purchasing an additional 63,505 shares during the period. Essex Investment Management Co. LLC grew its stake in shares of Revance Therapeutics by 26.6% during the second quarter. Essex Investment Management Co. LLC now owns 124,932 shares of the biopharmaceutical company’s stock worth $3,298,000 after purchasing an additional 26,248 shares during the period. Finally, Northern Trust Corp grew its stake in shares of Revance Therapeutics by 19.9% during the second quarter. Northern Trust Corp now owns 318,877 shares of the biopharmaceutical company’s stock worth $8,418,000 after purchasing an additional 52,940 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.
In other Revance Therapeutics news, Director Mark J. Foley bought 20,000 shares of the firm’s stock in a transaction on Tuesday, November 7th. The stock was purchased at an average cost of $26.96 per share, with a total value of $539,200.00. Following the completion of the purchase, the director now owns 6,000 shares in the company, valued at $161,760. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO L Daniel Browne sold 7,600 shares of the business’s stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $24.94, for a total value of $189,544.00. Following the completion of the transaction, the chief executive officer now directly owns 133,188 shares of the company’s stock, valued at $3,321,708.72. The disclosure for this sale can be found here. Over the last three months, insiders sold 44,026 shares of company stock valued at $1,135,234. Insiders own 18.86% of the company’s stock.
Revance Therapeutics, Inc. (NASDAQ:RVNC) opened at $26.50 on Friday. Revance Therapeutics, Inc. has a 52 week low of $15.85 and a 52 week high of $28.75.
Revance Therapeutics (NASDAQ:RVNC) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.06). Revance Therapeutics had a negative net margin of 37,161.00% and a negative return on equity of 67.85%. The business had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.05 million. During the same period in the previous year, the firm posted ($0.64) earnings per share. The firm’s revenue was up .0% on a year-over-year basis. equities research analysts forecast that Revance Therapeutics, Inc. will post -3.73 EPS for the current fiscal year.
A number of equities research analysts recently commented on the company. Zacks Investment Research cut Revance Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Mizuho assumed coverage on Revance Therapeutics in a research note on Thursday, November 16th. They set a “buy” rating and a $37.00 price objective for the company. Cantor Fitzgerald set a $50.00 price objective on Revance Therapeutics and gave the stock a “buy” rating in a research note on Thursday, November 16th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $28.00 price objective on shares of Revance Therapeutics in a research note on Friday, October 27th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $35.50.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://transcriptdaily.com/2017/11/26/the-manufacturers-life-insurance-company-has-483000-position-in-revance-therapeutics-inc-rvnc.html.
Revance Therapeutics Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Want to see what other hedge funds are holding RVNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revance Therapeutics, Inc. (NASDAQ:RVNC).
Receive News & Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.